Funding for neglected disease research and development (R&D) in 2017 reached its highest level ever, exceeding US$3.566 billion (€3.15 billion).
The figures are contained in the 11th annual G-FINDER report, the world's most comprehensive survey of R&D funding for neglected infectious diseases that disproportionately affect people in developing countries such as malaria, sleeping sickness and tuberculosis (TB).
According to the report, the public sector continued to be the most significant funding source for neglected disease research, contributing nearly two-thirds of the total. Significant new investments came from Europe, with the United Kingdom scaling up its contribution by 89 per cent to $186m, the European Commission by 50 per cent to $119m and the German government by 39 per cent to $65m. Public funding from low- and middle-income countries increased by 19 per cent to $105m, with India contributing nearly three-quarters of this total. The United States government was the world's largest public funder, providing an additional 1.5 per cent for a total of $1,595m.
However, despite the high figure of the record, overall funding levels fell below global targets.
As in previous years, HIV/AIDS, malaria and TB collectively received more than two-thirds of all global funding for neglected disease R&D in 2017.